Source: BioPortfolio

Inflazome: Inzomelid completes Phase I studies and shows positive results in the treatment of CryopyrinAssociated Periodic Syndrome CAPS

The Phase I study demonstrated Inzomelid has an excellent safety tolerability and pharmacokinetic profile in healthy subjects with dosedependent target engagementInzomelid also delivered positive preliminary results from a patient with CryopyrinAssociated ...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Matthew Cooper's photo - Co-Founder & CEO of Inflazome

Co-Founder & CEO

Matthew Cooper

CEO Approval Rating

89/100

Inflazome is a biotech company that develops and commercializes molecular-targeted drug therapies for the treatment of inflammatory diseases. Read more